“In India, we have deals with four major manufacturers. … India will produce about 300 million doses or more of the vaccine for us next year,” he told TASS news agency’s Rossiya 24 television channel Thursday.
RDIF is the sovereign wealth fund of Russia.
Dmitriev noted that out of 110 production sites that have negotiated the production of Sputnik V, RDIF has chosen 10 that meet its requirements.
“Russian Sputnik V will be actively produced around the world and we see that it is built on a secure platform based on human adenovirus,” Dmitriev said.
Earlier Dmitriev said that production of Sputnik V has started in other countries, most notably India, Korea, Brazil and China.
Registered by Russia on August 11, Sputnik V became the world’s first coronavirus vaccine.
The vaccine was developed by the Gamaleya National Research Center of Epidemiology and Microbiology.
Its post-registration trials began in Moscow on September 7, with volunteers receiving the first vaccine on September 9.
A total of 40,000 people are involved in the program.
RDIF supports the development of the Russian Covid-19 vaccine by the Gamaleya Center and is investing in the mass production of the vaccine by the companies in the RDIF portfolio.
gb / na